4.01
price down icon2.91%   -0.12
after-market After Hours: 4.04 0.03 +0.75%
loading
Evotec Se Adr stock is traded at $4.01, with a volume of 270.14K. It is down -2.91% in the last 24 hours and down -1.23% over the past month. Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
See More
Previous Close:
$4.13
Open:
$4.05
24h Volume:
270.14K
Relative Volume:
1.98
Market Cap:
$1.47B
Revenue:
$842.96M
Net Income/Loss:
$-185.63M
P/E Ratio:
-7.625
EPS:
-0.5259
Net Cash Flow:
$-228.52M
1W Performance:
-2.91%
1M Performance:
-1.23%
6M Performance:
-16.11%
1Y Performance:
-1.72%
1-Day Range:
Value
$4.01
$4.09
1-Week Range:
Value
$4.01
$4.44
52-Week Range:
Value
$2.84
$5.6405

Evotec Se Adr Stock (EVO) Company Profile

Name
Name
Evotec Se Adr
Name
Phone
-
Name
Address
-
Name
Employee
4,766
Name
Twitter
Name
Next Earnings Date
2025-04-17
Name
Latest SEC Filings
Name
EVO's Discussions on Twitter

Compare EVO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
EVO
Evotec Se Adr
4.01 1.47B 842.96M -185.63M -228.52M -0.5259
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
161.67 73.29B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.50 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.89 47.60B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.89 20.72B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
286.88 14.81B 2.99B 1.21B 1.13B 25.06

Evotec Se Adr Stock (EVO) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-24-25 Upgrade Deutsche Bank Sell → Hold
Oct-07-24 Downgrade Jefferies Buy → Hold
Aug-08-24 Downgrade Deutsche Bank Hold → Sell
Jul-29-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-11-24 Downgrade Deutsche Bank Buy → Hold
Apr-12-24 Upgrade Deutsche Bank Hold → Buy
Jan-18-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-23-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-23 Downgrade BofA Securities Buy → Neutral
Jun-08-23 Upgrade Citigroup Neutral → Buy
Apr-04-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Dec-09-22 Initiated H.C. Wainwright Buy
Nov-16-22 Downgrade Deutsche Bank Buy → Hold
Aug-10-22 Downgrade Morgan Stanley Overweight → Underweight
Mar-02-22 Resumed Cowen Outperform
Jan-07-22 Resumed Citigroup Neutral
View All

Evotec Se Adr Stock (EVO) Latest News

pulisher
Jun 04, 2025

8 New 4-Star Stocks - Morningstar

Jun 04, 2025
pulisher
May 24, 2025

Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister

May 24, 2025
pulisher
May 10, 2025

Evotec SE (EVO) Stock Forecasts - Yahoo Finance

May 10, 2025
pulisher
May 07, 2025

Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks

May 07, 2025
pulisher
May 07, 2025

Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks

May 07, 2025
pulisher
Apr 28, 2025

Stock Information - Evotec

Apr 28, 2025
pulisher
Apr 24, 2025

Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com

Apr 24, 2025
pulisher
Apr 18, 2025

Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia

Apr 18, 2025
pulisher
Apr 17, 2025

Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar

Apr 17, 2025
pulisher
Apr 11, 2025

Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts - GlobeNewswire Inc.

Apr 11, 2025
pulisher
Dec 29, 2024

Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha

Dec 29, 2024
pulisher
Dec 27, 2024

Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN

Dec 27, 2024
pulisher
Nov 25, 2024

Markets Brief: Are Bank Stocks Expensive? - Morningstar

Nov 25, 2024
pulisher
Nov 22, 2024

Evotec SE withdraws acquisition offer - Investing.com

Nov 22, 2024
pulisher
Nov 18, 2024

Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 17, 2024

Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - BNN Bloomberg

Nov 17, 2024
pulisher
Nov 14, 2024

Halozyme proposes $2 billion acquisition of Evotec - Investing.com

Nov 14, 2024
pulisher
Nov 06, 2024

Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks

Nov 06, 2024
pulisher
Oct 07, 2024

Evotec stock outlook clouded by strategy update delays, warns Jefferies - Investing.com

Oct 07, 2024
pulisher
Aug 23, 2024

Annual General Meeting - Evotec

Aug 23, 2024
pulisher
Aug 23, 2024

Investor Relations - Evotec

Aug 23, 2024
pulisher
Aug 13, 2024

Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar

Aug 13, 2024
pulisher
Jun 06, 2024

Healthcare Sector - Morningstar

Jun 06, 2024
pulisher
May 23, 2024

Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com

May 23, 2024
pulisher
Apr 24, 2024

Evotec: Still A Speculative Buy After A Significant Decline (NASDAQ:EVO) - Seeking Alpha

Apr 24, 2024
pulisher
Nov 10, 2022

Evotec SE ADR earnings, Revenue miss in Q3 By Investing.com - Investing.com India

Nov 10, 2022
pulisher
Jun 15, 2022

Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance

Jun 15, 2022
pulisher
Jan 21, 2012

Together for Medicines That MatterEvotec - Evotec

Jan 21, 2012
pulisher
May 11, 2010

Evotech and Roche subsidiary Genentech enter into drug discovery alliance - Proactive Investors USA

May 11, 2010
pulisher
Sep 09, 2009

Evotec and Biogen Idec in research agreement - Proactive financial news

Sep 09, 2009

Evotec Se Adr Stock (EVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$13.61
price down icon 2.72%
drug_manufacturers_specialty_generic RGC
$78.00
price up icon 30.00%
$8.76
price down icon 2.56%
$124.88
price down icon 0.10%
drug_manufacturers_specialty_generic RDY
$15.25
price down icon 2.99%
$286.88
price down icon 0.58%
Cap:     |  Volume (24h):